Novo Nordisk Licenses Nanexa's Coating Technology in a Deal Worth Up to 1.165 Billion Euros

The drugmaker gains a global exclusive license to the PharmaShell platform for up to five obesity and diabetes programs, aiming at monthly and quarterly dosing. Nanexa shares more than doubled in Stockholm.

By Anna Ferreira

Sep 26, 2026 · 7 min read

Novo Nordisk has licensed a Swedish drug-delivery technology that the companies say could stretch obesity and diabetes injections to monthly or quarterly dosing, in an agreement worth up to 1.165 billion euros, or about $1.33 billion, to the licensor.

Discussion (0)

Loading comments…

Anna Ferreira

Senior Correspondent, Corporate Strategy

Anna Ferreira writes for Corporate Insider Inc.

CII Briefing

The 7am memo for people who run things

One email. The deals, the numbers and the decisions that will be discussed in your Monday meeting.